Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer

Oncotarget

Volumn 7, Issue 24, 2016, Pages 35818-35831

  Xia, Yun ^a,b   Huang, Chiang Ching ^c   Dittmar, Rachel ^b   Du, Meijun ^b   Wang, Yuan ^b   Liu, Hongyan ^b   Shenoy, Niraj ^d   Wang, Liang ^b   Kohli, Manish ^d  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Cell free DNA; Liquid biopsy; Next generation sequencing; Prostate cancer; Urine

Indexed keywords

ANDROGEN RECEPTOR; CELL FREE DNA; DNA; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG; ANTIANDROGEN; ANTINEOPLASTIC AGENT; CELL FREE NUCLEIC ACID; DOCETAXEL; NOTCH1 PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; TAXOID; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ANDROGEN RECEPTOR GENE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE LOCUS; GENE SEQUENCE; HUMAN; MALE; MIDDLE AGED; NOTCH1 GENE; OVERALL SURVIVAL; PROSTATE CANCER; PTEN GENE; CHROMOSOME ABERRATION; DRUG EFFECTS; GENETICS; KAPLAN MEIER METHOD; OUTCOME ASSESSMENT; PROCEDURES; PROSTATE TUMOR; URINE;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL-FREE NUCLEIC ACIDS; CHROMOSOME ABERRATIONS; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECEPTOR, NOTCH1; RECEPTORS, ANDROGEN; TAXOIDS;

EID: 84978062670     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9027     Document Type: Article

References (41)

1. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5-29
2. Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong Y-N, Hahn N, Kohli M and Cooney MM. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. New England Journal of Medicine. 2015; 373:737-746
3. Petrylak DP, Tangen CM, Hussain MHA, Lara PN,. J., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New England Journal of Medicine. 2004; 351:1513-1520
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA and Investigators T. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine. 2004; 351:1502-1512
5. Denis LJ, Keuppens F, Smith PH, Whelan P, de Moura JL, Newling D, Bono A and Sylvester R. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol. 1998; 33:144-151
6. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ and Thompson Jr IM. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. New England Journal of Medicine. 1998; 339:1036-1042
7. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet. 2000; 355:1491-1498
8. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, et al. Abiraterone and Increased Survival in Metastatic Prostate Cancer. New England Journal of Medicine. 2011; 364:1995-2005
9. KantoffPW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R and Sims RB. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine. 2010; 363:411-422
10. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ and Shen L. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet. 2010; 376:1147-1154
11. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM and Ng S. Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine. 2013; 368:138-148
12. Cabot RC, Harris NL, Rosenberg ES, Shepard J-AO, Cort AM, Ebeling SH, McDonald EK, Scher HI, Fizazi K and Saad F. Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine. 2012; 367:1187-1197
13. Snedecor SJ, Carter JA, Kaura S and Botteman MF. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. Journal of medical economics. 2012; 16:19-29
14. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R and Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377:813-822
15. Crowley E, Di Nicolantonio F, Loupakis F and Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013; 10:472-484
16. Kohli M and Tindall DJ. New Developments in the Medical Management of Prostate Cancer. Mayo Clin Proc. 2010; 85:77-86
17. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castrationresistant prostate cancer. Journal of clinical oncology. 2009; 27:3742-3748
18. Diaz LA, Jr. and Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014; 32:579-586
19. Heitzer E, Ulz P and Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015; 61:112-123
20. Xia S, Kohli M, Du M, Dittmar RL, Lee A, Nandy D, Yuan T, Guo Y, Wang Y, Tschannen MR, Worthey E, Jacob H, See W, Kilari D, Wang X, Hovey RL, et al. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget. 2015; 6:16411-21. doi: 10.18632/oncotarget.3845
21. Witte JS, Goddard KA, Conti DV, Elston RC, Lin J, Suarez BK, Broman KW, Burmester JK, Weber JL and Catalona WJ. Genomewide scan for prostate cancer-aggressiveness loci. American journal of human genetics. 2000; 67:92-99
22. Kim JH, Dhanasekaran SM, Mehra R, Tomlins SA, Gu W, Yu J, Kumar-Sinha C, Cao X, Dash A, Wang L, Ghosh D, Shedden K, Montie JE, Rubin MA, Pienta KJ, Shah RB, et al. Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer research. 2007; 67:8229-8239
23. Tindall EA, Severi G, Hoang HN, Ma CS, Fernandez P, Southey MC, English DR, Hopper JL, Heyns CF, Tangye SG, Giles GG, Hayes VM and Australian Prostate Cancer B. Comprehensive analysis of the cytokine-rich chromosome 5q31.1 region suggests a role for IL-4 gene variants in prostate cancer risk. Carcinogenesis. 2010; 31:1748-1754
24. Porkka KP, Tammela TLJ, Vessella RL and Visakorpi T. RAD21 and KIAA0196 at 8q24 are amplified and overexpressed in prostate cancer. Genes, Chromosomes and Cancer. 2004; 39:1-10
25. Tuupanen S, Turunen M, Lehtonen R, Hallikas O, Vanharanta S, Kivioja T, Björklund M, Wei G, Yan J and Niittymäki I. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nature genetics. 2009; 41:885-890
26. Saramäki OR, Porkka KP, Vessella RL and Visakorpi T. Genetic aberrations in prostate cancer by microarray analysis. International journal of cancer. 2006; 119:1322-1329
27. Ellen TP, Ke Q, Zhang P and Costa M. NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states. Carcinogenesis. 2008; 29:2-8
28. Wang Z, Li Y, Banerjee S, Kong D, Ahmad A, Nogueira V, Hay N and Sarkar FH. Down-regulation of Notch -1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-B signaling pathways. J Cell Biochem. 2010; 109:726-736
29. Bin Hafeez B, Adhami VM, Asim M, Siddiqui IA, Bhat KM, Zhong W, Saleem M, Din M, Setaluri V and Mukhtar H. Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clinical cancer research. 2009; 15:452-459
30. Botezatu I, Serdyuk O, Potapova G, Shelepov V, Alechina R, Molyaka Y, Ananev V, Bazin I, Garin A, Narimanov M, Knysh V, Melkonyan H, Umansky S and Lichtenstein A. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem. 2000; 46:1078-1084
31. Lichtenstein AV, Melkonyan HS, Tomei LD and Umansky SR. Circulating nucleic acids and apoptosis. Annals of the New York Academy of Sciences. 2001; 945:239-249
32. De Mattos-Arruda L, Cortes J, Santarpia L, Vivancos A, Tabernero J, Reis-Filho JS and Seoane J. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nature reviews Clinical oncology. 2013; 10:377-389
33. Emile JF, Diamond EL, Helias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Hyman DM, Kim E, Rampal R, Patel M, Ganzel C, Aumann S, Faucher G, Le Gall C, Leroy K, Colombat M, Kahn JE, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 2014; 124:3016-3019
34. Diamond EL, Abdel-Wahab O, Pentsova E, Borsu L, Chiu A, Teruya-Feldstein J, Hyman DM and Rosenblum M. Detection of an NRAS mutation in Erdheim-Chester disease. Blood. 2013; 122:1089-1091
35. Zebisch M and Jones EY. ZNRF3/RNF43-A direct linkage of extracellular recognition and E3 ligase activity to modulate cell surface signalling. Progress in biophysics and molecular biology. 2015; 118:112-8
36. Nakata S, Phillips E and Goidts V. Emerging role for leucine-rich repeat-containing G-protein-coupled receptors LGR5 and LGR4 in cancer stem cells. Cancer management and research. 2014; 6:171
37. Hsieh AL, Walton ZE, Altman BJ, Stine ZE and Dang CV. MYC and metabolism on the path to cancer. Semin Cell Dev Biol. 2015
38. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161:1215-1228
39. Kato S and Janku F. Cell-free DNA as a novel marker in cancer therapy. Biomarkers in medicine. 2015; 9:703-712
40. Diskin SJ, Li M, Hou C, Yang S, Glessner J, Hakonarson H, Bucan M, Maris JM and Wang K. Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms. Nucleic Acids Res. 2008; 36:e126
41. Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castrationresistant prostate cancer. Eur Urol. 2015; 67:33-41